Collplant Biotechnologies Net Worth
Collplant Biotechnologies Net Worth Breakdown | CLGN |
Collplant Biotechnologies Net Worth Analysis
Collplant Biotechnologies' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Collplant Biotechnologies' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Collplant Biotechnologies' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Collplant Biotechnologies' net worth analysis. One common approach is to calculate Collplant Biotechnologies' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Collplant Biotechnologies' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Collplant Biotechnologies' net worth. This approach calculates the present value of Collplant Biotechnologies' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Collplant Biotechnologies' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Collplant Biotechnologies' net worth. This involves comparing Collplant Biotechnologies' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Collplant Biotechnologies' net worth relative to its peers.
Enterprise Value |
|
To determine if Collplant Biotechnologies is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Collplant Biotechnologies' net worth research are outlined below:
| Collplant Biotechnologies generated a negative expected return over the last 90 days | |
| Collplant Biotechnologies has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 10.96 M. Net Loss for the year was (7.02 M) with profit before overhead, payroll, taxes, and interest of 13.64 M. | |
| Collplant Biotechnologies currently holds about 36.29 M in cash with (2.76 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.27. | |
| Collplant Biotechnologies has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: CollPlant to Report Q3 2024 Earnings on Nov 27 Conference Call Details CLGN Stock News - StockTitan |
Collplant Biotechnologies uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Collplant Biotechnologies. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Collplant Biotechnologies' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 3rd of April 2024 Upcoming Quarterly Report | View | |
| 22nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 3rd of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Collplant Biotechnologies' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Collplant Biotechnologies is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Collplant Biotechnologies backward and forwards among themselves. Collplant Biotechnologies' institutional investor refers to the entity that pools money to purchase Collplant Biotechnologies' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Parallel Advisors, Llc | 2024-06-30 | 3.3 K |
Follow Collplant Biotechnologies' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 48.85 M.Market Cap |
|
Project Collplant Biotechnologies' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.21) | (0.22) | |
| Return On Capital Employed | (0.24) | (0.26) | |
| Return On Assets | (0.21) | (0.22) | |
| Return On Equity | (0.25) | (0.26) |
When accessing Collplant Biotechnologies' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Collplant Biotechnologies' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Collplant Biotechnologies' profitability and make more informed investment decisions.
Evaluate Collplant Biotechnologies' management efficiency
Collplant Biotechnologies has return on total asset (ROA) of (0.3377) % which means that it has lost $0.3377 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6155) %, meaning that it created substantial loss on money invested by shareholders. Collplant Biotechnologies' management efficiency ratios could be used to measure how well Collplant Biotechnologies manages its routine affairs as well as how well it operates its assets and liabilities. As of the 28th of November 2024, Return On Tangible Assets is likely to drop to -0.22. In addition to that, Return On Capital Employed is likely to drop to -0.26. At this time, Collplant Biotechnologies' Other Current Assets are very stable compared to the past year. As of the 28th of November 2024, Intangible Assets is likely to grow to about 265.7 K, while Total Assets are likely to drop about 18.2 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.49 | 2.77 | |
| Tangible Book Value Per Share | 2.47 | 2.59 | |
| Enterprise Value Over EBITDA | (7.69) | (7.30) | |
| Price Book Value Ratio | 2.57 | 4.81 | |
| Enterprise Value Multiple | (7.69) | (7.30) | |
| Price Fair Value | 2.57 | 4.81 | |
| Enterprise Value | 49.3 M | 59.3 M |
At Collplant Biotechnologies, effective management practices are pivotal to sustaining long-term profitability. We delve into financial metrics and market conditions to provide a comprehensive analysis of the stock's prospects.
Enterprise Value Revenue 48.2347 | Revenue 689 K | Quarterly Revenue Growth (0.98) | Revenue Per Share 0.06 | Return On Equity (0.62) |
Collplant Biotechnologies Corporate Filings
6K | 27th of November 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
| 4th of April 2024 Other Reports | ViewVerify | |
13A | 13th of February 2024 An amended filing to the original Schedule 13G | ViewVerify |
Collplant Biotechnologies Earnings per Share Projection vs Actual
Collplant Biotechnologies Corporate Management
| Oren Fahimipoor | Vice Operations | Profile | |
| Michal Roytman | VP Marketing | Profile | |
| Pr Shoseyov | Founder Scientist | Profile | |
| Eran CPA | Deputy CFO | Profile | |
| Elana Gazal | Vice Development | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Collplant Biotechnologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Collplant Stock, please use our How to Invest in Collplant Biotechnologies guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Collplant Biotechnologies. If investors know Collplant will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Collplant Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.53) | Revenue Per Share 0.06 | Quarterly Revenue Growth (0.98) | Return On Assets (0.34) | Return On Equity (0.62) |
The market value of Collplant Biotechnologies is measured differently than its book value, which is the value of Collplant that is recorded on the company's balance sheet. Investors also form their own opinion of Collplant Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Collplant Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Collplant Biotechnologies' market value can be influenced by many factors that don't directly affect Collplant Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Collplant Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Collplant Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Collplant Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.